Ascendis Pharma A/S ADR (NASDAQ: ASND) kicked off on Friday, down -2.65% from the previous trading day, before settling in for the closing price of $131.62. Over the past 52 weeks, ASND has traded in a range of $111.09-$161.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 222.52%. While this was happening, its average annual earnings per share was recorded 18.09%. With a float of $59.25 million, this company’s outstanding shares have now reached $59.76 million.
In terms of profitability, gross margin is 84.82%, operating margin of -96.44%, and the pretax margin is -127.34%.
Ascendis Pharma A/S ADR (ASND) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ascendis Pharma A/S ADR is 0.86%, while institutional ownership is 105.00%. The most recent insider transaction that took place on Dec 10 ’24, was worth 273,621. Before that another transaction happened on Dec 10 ’24, when Company’s Officer proposed sale 2,119 for $129.13, making the entire transaction worth $273,621.
Ascendis Pharma A/S ADR (ASND) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 18.09% per share during the next fiscal year.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Trading Performance Indicators
Take a look at Ascendis Pharma A/S ADR’s (ASND) current performance indicators. Last quarter, stock had a quick ratio of 0.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.10, a number that is poised to hit -1.18 in the next quarter and is forecasted to reach -4.04 in one year’s time.
Technical Analysis of Ascendis Pharma A/S ADR (ASND)
The latest stats from [Ascendis Pharma A/S ADR, ASND] show that its last 5-days average volume of 0.44 million was superior to 0.44 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 32.14%. Additionally, its Average True Range was 5.66.
During the past 100 days, Ascendis Pharma A/S ADR’s (ASND) raw stochastic average was set at 38.34%, which indicates a significant increase from 11.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.63% in the past 14 days, which was lower than the 46.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $132.34, while its 200-day Moving Average is $134.05. Now, the first resistance to watch is $131.81. This is followed by the second major resistance level at $135.48. The third major resistance level sits at $137.59. If the price goes on to break the first support level at $126.03, it is likely to go to the next support level at $123.92. The third support level lies at $120.25 if the price breaches the second support level.
Ascendis Pharma A/S ADR (NASDAQ: ASND) Key Stats
The company with the Market Capitalisation of 7.66 billion has total of 60,689K Shares Outstanding. Its annual sales at the moment are 288,670 K in contrast with the sum of -521,070 K annual income. Company’s last quarter sales were recorded 63,590 K and last quarter income was -109,080 K.
